Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses
Open Access
- 9 September 2025
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (37)
Abstract
Major depressive disorder affects millions worldwide, yet current treatments require prolonged administration. In contrast, ketamine produces rapid antidepressant effects by blocking spontaneous N-Methyl-D-Aspartate (NMDA) receptor signaling, which lifts the suppression of protein synthesis and triggers homeostatic synaptic plasticity. Here, we identify a parallel signaling pathway involving metabotropic glutamate receptor 5 (mGluR5) that promotes rapid antidepressant-like effects. We show that enhancing the endogenous mGluR5 signaling produces synaptic potentiation in the hippocampus and triggers the rapid antidepressant effect, similar to ketamine. Importantly, blocking mGluR5 prevents ketamine’s effects, revealing a synergy between the two pathways. At the cellular level, spontaneous calcium transients mediated by mGluR5 activate the phosphatase calcineurin and promote eukaryotic elongation factor 2 (eEF2) dephosphorylation, increasing BDNF translation to drive synaptic plasticity. We show that quantal glutamate release activates two spatially segregated Ca 2+ signals—NMDAR- and mGluR5-driven—which exert opposing effects on protein synthesis. Together, these findings highlight mGluR5 as a promising therapeutic target for rapid antidepressant action, harnessing the complex nanoscale organization of synapses.Keywords
Funding Information
- HHS | NIH | National Institute of Neurological Disorders and Stroke (NS134128)
- HHS | NIH | National Institute of Mental Health (MH070727)
- Brain and Behavior Research Foundation (NARSAD Award 32272)
This publication has 63 references indexed in Scilit:
- Depression-like effects induced by chronic unpredictable mild stress in mice are rapidly reversed by a partial negative allosteric modulator of mGlu5 receptor, M-5MPEPPsychopharmacology, 2024
- Partial mGlu5 receptor NAM, M-5MPEP, induces rapid and sustained antidepressant-like effects in the BDNF-dependent mechanism and enhances (R)-ketamine action in micePharmacological Reports, 2024
- The role of mGluR5 on the therapeutic effects of ketamine in Wistar ratsPsychopharmacology, 2024
- Convergence of distinct signaling pathways on synaptic scaling to trigger rapid antidepressant actionCell Reports, 2021
- A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant actionCell Reports, 2021
- In Vivo Ketamine-Induced Changes in [ 11 C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5Biological Psychiatry, 2015
- Amyloid beta deregulates astroglial mGluR5‐mediated calcium signaling via calcineurin and Nf‐kBGlia, 2013
- Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depressionBehavioural Brain Research, 2013
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brainJournal of Comparative Neurology, 1995